US 12,453,738 B2
Treatment of oncogene-driven cancers
Joanne B.L. Tan, San Francisco, CA (US); Akshata R. Udyavar, Foster City, CA (US); and Stephen W. Young, Palomar Park, CA (US)
Assigned to ARCUS BIOSCIENCES, INC., Hayward, CA (US)
Appl. No. 17/438,186
Filed by ARCUS BIOSCIENCES, INC., Hayward, CA (US)
PCT Filed Mar. 11, 2020, PCT No. PCT/US2020/022028
§ 371(c)(1), (2) Date Sep. 10, 2021,
PCT Pub. No. WO2020/185859, PCT Pub. Date Sep. 17, 2020.
Claims priority of provisional application 62/817,425, filed on Mar. 12, 2019.
Prior Publication US 2022/0241313 A1, Aug. 4, 2022
Int. Cl. A61K 31/7076 (2006.01); A61K 31/282 (2006.01); A61K 31/506 (2006.01); A61K 31/704 (2006.01); A61K 31/7064 (2006.01); A61K 33/243 (2019.01); A61K 39/395 (2006.01); A61P 35/00 (2006.01)
CPC A61K 31/7076 (2013.01) [A61K 31/282 (2013.01); A61K 31/506 (2013.01); A61K 31/704 (2013.01); A61K 31/7064 (2013.01); A61K 33/243 (2019.01); A61K 39/3955 (2013.01); A61P 35/00 (2018.01)] 8 Claims
 
1. A method of treating a subject identified as having an oncogene driven cancer comprising administering to said subject a therapeutically effective amount of Compound A

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof;
and wherein the an oncogene driven cancer has a mutation in KRAS.